152 related articles for article (PubMed ID: 37093458)
1. Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.
Lim SYM; Al Bishtawi B; Lim W
Eur J Drug Metab Pharmacokinet; 2023 May; 48(3):221-240. PubMed ID: 37093458
[TBL] [Abstract][Full Text] [Related]
2. S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.
Tran L; Nikanjam M; Capparelli EV; Bertino JS; Nafziger AN; Kashuba ADM; Turpault S; Ma JD
Eur J Clin Pharmacol; 2021 Sep; 77(9):1349-1356. PubMed ID: 33754183
[TBL] [Abstract][Full Text] [Related]
3. Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients.
Deb S; Arrighi S
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):185-203. PubMed ID: 33538960
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
Huth F; Gardin A; Umehara K; He H
Clin Pharmacol Ther; 2019 Nov; 106(5):1113-1124. PubMed ID: 31199498
[TBL] [Abstract][Full Text] [Related]
5. Variations in prothrombin time-international normalized ratio caused by drug-drug interaction in patients receiving warfarin: A retrospective observational study.
Shiraishi C; Hirai T; Fujita S; Dohi K; Iwamoto T
Int J Clin Pharmacol Ther; 2023 Apr; 61(4):139-147. PubMed ID: 36633369
[TBL] [Abstract][Full Text] [Related]
6. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.
Castellan AC; Tod M; Gueyffier F; Audars M; Cambriels F; Kassaï B; Nony P;
Clin Pharmacokinet; 2013 Mar; 52(3):199-209. PubMed ID: 23344982
[TBL] [Abstract][Full Text] [Related]
7. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
Zhou SF; Zhou ZW; Yang LP; Cai JP
Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
[TBL] [Abstract][Full Text] [Related]
9. Interactions of herbs with cytochrome P450.
Zhou S; Gao Y; Jiang W; Huang M; Xu A; Paxton JW
Drug Metab Rev; 2003 Feb; 35(1):35-98. PubMed ID: 12635815
[TBL] [Abstract][Full Text] [Related]
10. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies.
Qiu JX; Zhou ZW; He ZX; Zhang X; Zhou SF; Zhu S
Drug Des Devel Ther; 2015; 9():841-66. PubMed ID: 25733806
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
13. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
15. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
16. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
[TBL] [Abstract][Full Text] [Related]
17. Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity.
Lim SYM; Binti Azidin AR; Ung YT; Al-Shagga M; Alshawsh MA; Mohamed Z; Ong CE; Pan Y
Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):423-431. PubMed ID: 30306496
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
[TBL] [Abstract][Full Text] [Related]
20. Effects of catalpol on the activity of human liver cytochrome P450 enzymes.
Liu L; Cao X; Li T; Li X
Xenobiotica; 2019 Nov; 49(11):1289-1295. PubMed ID: 30557096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
